# Elizabeth Douville

> Elizabeth Douville is a Series A investor at GeneChem backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [GeneChem](https://shizune.co/investors/profile/genechem)
- Location: Montréal, Canada
- Total investments: 5
- Last investment: Oct 2022
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/elizabeth-douville-22a35bb/

Elizabeth Douville is a Series A investor at GeneChem in Montréal focused on Biotechnology and Health Care. Dr. Douville joined GeneChem in 1997 as a Manager of the Technologies Fund and was promoted to Vice President in 2001 with the raising of their Therapeutics Fund. In 2006, Dr. Douville became General Partner with the raising of their third fund, AgeChem. As of January 2011, Dr. Douville is co-managing the fourth and latest venture fund, AmorChem.Dr. Douville is an active board member of Alethia Biotherapeutics and she was an active member of the boards of directors of Cytochroma Inc., Ambit Biosciences Inc., LymphoSign Inc. and Chronogen Inc. and was also a board member of Idun Pharmaceuticals Inc. before its sale to Pfizer in 2005. Elizabeth obtained her Ph.D. in biochemistry at the University of Ottawa (1994), studying the role of protein tyrosine kinases in oncogenesis. She then received postdoctoral training at the Imperial Cancer Research Fund in London (U.K.) from 1994 to 1997 where she studied oncogenes and their signal transduction pathways. In 2008, Elizabeth obtained a business certificate degree as part of the “Programme de perfectionnement des cadres supérieurs” (an Executive management and training program) offered by CIREM in collaboration with HEC/University of Montreal.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Health Care | 2 | 40% |
| Therapeutics | 2 | 40% |
| Medical | 1 | 20% |
| Diabetes | 1 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Funding Round | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M | Series C | Oct 17, 2022 |  |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $35M | Series B | Sep 08, 2020 |  |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $7M | Series A | Jul 25, 2018 |  |
| Semathera | SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada). | $2.6M |  | Mar 26, 2018 |  |
| Alethia BioTherapeutics | Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $9.2M | Series A | Sep 07, 2010 |  |

5 of 5 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 5 deals together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 3 deals together
- [JDRF T1D Fund](https://shizune.co/investors/profile/jdrf-t1d-fund) — VC Fund, 3 deals together
- [adMare Bio Innovations](https://shizune.co/investors/profile/admare-bio-innovations) — VC Fund, 2 deals together
- [AQC Capital](https://shizune.co/investors/profile/anges-qu%C3%A9bec-capital) — VC Fund, 2 deals together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 2 deals together

## About GeneChem

VC Fund · Montréal, Canada

GeneChem fund and the changing landscape of the genomics industry, the principals set out to raise their second focused fund, GeneChem Therapeutics Venture Fund L.P.. With committed capital of $136.5 million, the Therapeutics Fund's objectives were to invest within the genomics industry but specifically in companies developing therapeutics forproliferative disorders including cancer, infectious diseases, inflammation and diabetes.

5 contacts available at GeneChem.

| Name | Title | Profile |
| --- | --- | --- |
| Elizabeth Douville | General Partner | https://shizune.co/investors/profile/lizabeth-douville |
| Maxime Pesant | Vice-President, Finance | https://shizune.co/investors/profile/maxime-pesant |
| Fabienne Perreau | Administrative Assistant | https://shizune.co/investors/profile/fabienne-perreau |
| Inès Holzbaur | General Partner | https://shizune.co/investors/profile/ins-holzbaur |
| John Clement | General Partner | https://shizune.co/investors/profile/john-clement |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Elizabeth Douville invest in?

Elizabeth Douville invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Elizabeth Douville last invest?

The most recent investment recorded for Elizabeth Douville closed in Oct 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co